Cargando…
Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs
BACKGROUND: Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. METHODS: Three negative controlled, randomized studies were conducted in dogs to evalua...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263043/ https://www.ncbi.nlm.nih.gov/pubmed/25471474 http://dx.doi.org/10.1186/s13071-014-0567-6 |
_version_ | 1782348496455598080 |
---|---|
author | Taenzler, Janina Wengenmayer, Christina Williams, Heike Fourie, Josephus Zschiesche, Eva Roepke, Rainer KA Heckeroth, Anja R |
author_facet | Taenzler, Janina Wengenmayer, Christina Williams, Heike Fourie, Josephus Zschiesche, Eva Roepke, Rainer KA Heckeroth, Anja R |
author_sort | Taenzler, Janina |
collection | PubMed |
description | BACKGROUND: Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. METHODS: Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1 study) and the speed of flea kill (2 studies) of fluralaner. All dogs were infested prior to treatment with unfed adult C. felis fleas. Dogs in the treated groups were administered once orally with fluralaner at a minimum dose of 25 mg/kg body weight, while dogs in the control groups were not treated. Separate control and treatment groups were paired at each time point of flea assessment. Flea counts were performed by combing dogs at either 0.5, 1, 2, or 4 hours after fluralaner treatment to measure the start to kill. To evaluate the speed of flea kill over 12 weeks, flea counts were performed by combing dogs at either 4, 8, 12, or 24 hours after fluralaner treatment and then at 4, 8, 12, or 24 hours after each flea re-infestations performed at 4, 8, and 12 weeks following treatment. RESULTS: In the start to kill study, the fluralaner activity against fleas started already at 1 hour post-treatment (8% numerical efficacy). At 2 and 4 hours post-treatment, the flea reduction was significant with 36.7% and 88% efficacy, respectively. In the speed of kill studies, the efficacy against fleas after fluralaner treatment was 80.5% at 4 hours and remained ≥ 99.4% at 8, 12 and 24 hours. After flea re-infestations in weeks 4, 8 and 12, the efficacy at 4 hours was 96.8, 91.4, and 33.5%, respectively. Efficacy at 8, 12 and 24 hours after flea re-infestations was 98.0-100% for the 12 weeks of the study. Except for 4 hours after the 12-week flea re-infestation, flea reduction was significant for all time points after flea re-infestation. CONCLUSIONS: Single oral fluralaner administration rapidly eliminates existing flea infestations and provides excellent protection against fleas over 12 weeks following treatment. |
format | Online Article Text |
id | pubmed-4263043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42630432014-12-12 Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs Taenzler, Janina Wengenmayer, Christina Williams, Heike Fourie, Josephus Zschiesche, Eva Roepke, Rainer KA Heckeroth, Anja R Parasit Vectors Research BACKGROUND: Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. METHODS: Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1 study) and the speed of flea kill (2 studies) of fluralaner. All dogs were infested prior to treatment with unfed adult C. felis fleas. Dogs in the treated groups were administered once orally with fluralaner at a minimum dose of 25 mg/kg body weight, while dogs in the control groups were not treated. Separate control and treatment groups were paired at each time point of flea assessment. Flea counts were performed by combing dogs at either 0.5, 1, 2, or 4 hours after fluralaner treatment to measure the start to kill. To evaluate the speed of flea kill over 12 weeks, flea counts were performed by combing dogs at either 4, 8, 12, or 24 hours after fluralaner treatment and then at 4, 8, 12, or 24 hours after each flea re-infestations performed at 4, 8, and 12 weeks following treatment. RESULTS: In the start to kill study, the fluralaner activity against fleas started already at 1 hour post-treatment (8% numerical efficacy). At 2 and 4 hours post-treatment, the flea reduction was significant with 36.7% and 88% efficacy, respectively. In the speed of kill studies, the efficacy against fleas after fluralaner treatment was 80.5% at 4 hours and remained ≥ 99.4% at 8, 12 and 24 hours. After flea re-infestations in weeks 4, 8 and 12, the efficacy at 4 hours was 96.8, 91.4, and 33.5%, respectively. Efficacy at 8, 12 and 24 hours after flea re-infestations was 98.0-100% for the 12 weeks of the study. Except for 4 hours after the 12-week flea re-infestation, flea reduction was significant for all time points after flea re-infestation. CONCLUSIONS: Single oral fluralaner administration rapidly eliminates existing flea infestations and provides excellent protection against fleas over 12 weeks following treatment. BioMed Central 2014-12-04 /pmc/articles/PMC4263043/ /pubmed/25471474 http://dx.doi.org/10.1186/s13071-014-0567-6 Text en © Taenzler et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Taenzler, Janina Wengenmayer, Christina Williams, Heike Fourie, Josephus Zschiesche, Eva Roepke, Rainer KA Heckeroth, Anja R Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title | Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title_full | Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title_fullStr | Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title_full_unstemmed | Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title_short | Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs |
title_sort | onset of activity of fluralaner (bravecto™) against ctenocephalides felis on dogs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263043/ https://www.ncbi.nlm.nih.gov/pubmed/25471474 http://dx.doi.org/10.1186/s13071-014-0567-6 |
work_keys_str_mv | AT taenzlerjanina onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT wengenmayerchristina onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT williamsheike onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT fouriejosephus onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT zschiescheeva onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT roepkerainerka onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs AT heckerothanjar onsetofactivityoffluralanerbravectoagainstctenocephalidesfelisondogs |